{
    "clinical_study": {
        "@rank": "8269", 
        "arm_group": {
            "arm_group_label": "ArterX Surgical Sealant", 
            "arm_group_type": "Other"
        }, 
        "brief_summary": {
            "textblock": "The study is designed to confirm the acute safety and performance of the ArterX\u00ae Surgical\n      Sealant as a hemostatic agent.  The study will collect data in support of publications and\n      future product labeling revisions, to provide additional clinical information on use and\n      further details regarding product safety."
        }, 
        "brief_title": "ArterX Safety and Efficacy Study for Cardiac Indications", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Vascular Disease", 
        "condition_browse": {
            "mesh_term": "Vascular Diseases"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        >18 years of age, Male or female If female, subject is post-menopausal, has no child\n        bearing potential or has a negative serum or urine pregnancy test within 7 days of the\n        index procedure and is practicing abstinence or a highly effective method of contraception\n        for the duration of the study.\n\n        The subject or guardian must provide written Informed Consent using a form that is\n        reviewed and approved by the Ethics Committee.\n\n        The subject is willing and able to be contacted for 3 months follow-up and attend\n        follow-up visits as needed per protocol.\n\n        The subject is determined by the surgeon to be at risk for poor hemostasis.\n\n        Exclusion Criteria:\n\n        Subject undergoing emergency surgery. Subject undergoing minimally invasive surgery.\n        Subject has clinically significant medical, psychiatric, or cognitive illness or\n        drug/alcohol abuse that in the opinion of the investigator would affect the subject's\n        safety or compliance with study assessments or follow-up.\n\n        Subject has immune system disorders/immunodeficiency or immunosuppression. Subject has\n        participated in another clinical study within 30 days prior to surgery or has received an\n        investigational drug or device within the past 30 days.\n\n        Subject is pregnant, may become pregnant or is currently breast feeding\n\n        -"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "45", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 27, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01957904", 
            "org_study_id": "CLN-015"
        }, 
        "intervention": {
            "arm_group_label": "ArterX Surgical Sealant", 
            "intervention_name": "ArterX Surgical Sealant", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "ArterX, surgical sealant", 
        "lastchanged_date": "October 7, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Trier", 
                    "country": "Germany"
                }, 
                "name": "Krankenhaus Der Barmherzigen Bruder"
            }
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "1", 
        "official_title": "Prospective, Multi-Center, Open-Label, Post-Market ArterX\u00ae Safety and Efficacy Study Protocol for Cardiac Indications", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Germany: Bundesministerium f\u00fcr Gesundheit", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Immediate sealing of the suture/staple line at point of use upon release of the clamps, as evidenced by an absence of clinically significant bleeding  as determined by physician investigator in procedures completed using the ArterX device.", 
            "measure": "Number of subjects with immediate sealing of suture/staple line", 
            "safety_issue": "No", 
            "time_frame": "during surgery"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01957904"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Tenaxis Medical, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Tenaxis Medical, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}